This article is more than 5 years old. Information may no longer be current.

Liquid botulinum toxin type A demonstrates comparability to Botox for treatment of glabellar lines

Researchers found liquid-type botulinum toxin type A to be comparable to Botox for the treatment of glabellar lines in a population of Korean patients.

Liquid-type botulinum toxin type A (MT101091L) provides convenience because it does not require dilution and has long-lasting effects, according to the researchers.

In a prospective, randomized, double-blind, parallel, active drug-controlled, phase 3 clinical trial, the researchers enrolled 159 Korean men and women between the ages of 20 and 65 years. Patients were randomly assigned to receive treatment with MT10109L or Botox (onabotulinumtoxin A, Allergan) and were assessed at 4, 10 and 16 weeks by physician investigators and subjective patient assessment. Standard digital photos were used for live assessment of glabellar severity, evaluated at rest and maximum frown, using the Facial Wrinkle Scale.

Both groups showed significant improvement of glabellar lines at week 4, and improvement lasted until week 16, according to the researchers.

The improvement of glabellar lines at rest based on the investigators’ live assessment and photographic assessment was similar in both treatment groups.

The percentage of responders at maximum frown by live assessment at week 16 was significantly lower in the onabotulinumtoxin A group than in the MT101091L group. However, at week 16, the improvement by live assessment was significantly higher in the MT101091L group compared with the onabotulinumtoxin A group, according to the researchers.

Overall, no serious adverse events were reported. – by Abigail Sutton

Disclosure: The researchers report no relevant financial disclosures.